Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

Phase 2

Terminated

Conditions: HNSCC

Interventions: Drug: Bimiralisib

Registration Number: NCT03740100

Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary: Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition (phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibition).

The current study enrolls patients with refractory and / or metastatic Head and Neck Squameous Cell Carcinoma based on the mutational status of their disease to assess the response to treatment with bimiralisib, an orally available pan-PI3K/mTOR inhibitor (phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibitor).

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 8

Inclusion Criteria

Histologically or cytological confirmed diagnosis of Head and Neck Squameous Cell Carcinoma, for which no standard curative or life prolonging therapy is available
Available CLIA-certified sequencing results of the NOTCH gene in Head and Neck Squameous Cell Carcinoma (HNSCC) tumor material. The tumor must harbor a NOTCH1 LOF mutation as confirmed by central review (MD Anderson Cancer Center, MDACC)
ECOG performance status of ≤ 2
Adequate bone marrow, liver, and renal functions
Measurable disease according to RECIST version 1.1
Patients of reproductive potential must agree to use effective contraception from screening until 90 days after discontinuing study treatment.

Exclusion Criteria

Has received any anti-cancer treatment including hormonal and investigational agents within 21 days prior to first dose of bimiralisib.
Major surgery within 28 days prior to first dose of bimiralisib or persisting side effects that have not improved to NCI-CTCAE grade 1 or better.
Pregnant or nursing (lactating) women.
Poorly controlled diabetes mellitus, steroid-induced diabetes mellitus
Has other active malignancies that require systemic treatment.
Has a known history of HIV infection
Any of the following cardiac abnormalities:
- History of, or current, documented congestive heart failure (New York heart association functional classification iii - iv), documented cardiomyopathy
- Symptomatic (NYHA class II or higher) left ventricular ejection fraction (LVEF) < 40% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (echo)
- Myocardial infarction ≤ 6 months prior to enrolment
- Unstable angina pectoris
- Serious uncontrolled cardiac arrhythmia
- Symptomatic pericarditis
Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
Patient has a history of non-compliance to medical regimen or inability to grant consent.
Medically documented history of an active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or ≥ CTCAE grade 3 anxiety
History of interstitial pneumonitis or patients who require chronic oxygen supplementation.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open single arm	Bimiralisib	Bimiralisib capsules orally

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	At 6 and 12 weeks after the start of therapy (± 3 days)	Radiological tumor assessments were performed by computed tomography (CT) or magnetic resonance imaging (MRI) according to a standard protocol. ORR: comprised of all patients who achieved a confirmed partial or a confirmed complete response per RECIST 1.1

Secondary Outcome Measures